Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to Association of the British Pharmaceutical Industry’s publication entitled At the crossroads: how a new UK medicines deal can deliver for patients, the NHS and the economy, published on 1 March 2023, what assessment he has made of the potential implications for his policies of that publication's proposals to lower the tax rebate for the voluntary scheme for branded medicines pricing and access.

The Department carefully considers all evidence in the public domain on matters relating to the pricing of medicines in the United Kingdom, including the March report by the Association of the British Pharmaceutical Industry (ABPI).

The Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) has been agreed in principle with ABPI and is set to save the National Health Service £14 billion over 5 years in medicines costs. VPAG introduces a new mechanism to ensure sustainable spending on older medicines where competition hasn’t yet driven down prices, and is an explicitly pro-innovation and pro-competition agreement.